Comprehensive Market Access Strategy Support At All Lifecycle Stages

ASSESS the landscape, MITIGATE risks, OPTIMIZE market access success in Canada.

Our team of experts use their unique combination of real-world experience, technical skill, and nuanced understanding of the Canadian payer context to provide honest and practical guidance.

Early Pipeline

Market Access Landscape, Pricing, & Analogue Assessment
Canadian Reimbursement & Forecasting Timeline (CRaFT) Report
Pipeline Assessment
RWE Planning & Evidence Strategy

Prior to Launch

HTA Submission Strategy & Review
PE Modelling Strategy (Global & Local)
Advisory Board Facilitation
Innovative Agreement Assessment
Stakeholder Mapping, Insight Gathering, & Engagement Plan

Time of Commercialization

pCPA Assessment (pan-Canadian Pharmaceutical Alliance)
Negotiation Strategy Development
Simulated Negotiations & Ongoing Support
MORSE Advisory Panels

Portfolio & Life Cycle Strategy

Risk Assessments
Re-negotiation Strategy
Generic Entry Assessment & Strategy
Multiple Indication Strategy

Explore MORSE’s Market Access Service Offerings Here or Download Our Brochure to Learn More

We also offer various Canadian Market Access Trends & Insights Reports

Essential knowledge for new and existing companies entering the Canadian market with new drugs
Tailored reports focused on oncology and rare diseases, addressing unique challenges and opportunities
Guides international companies through the complexities of the Canadian market
Crucial insights into the Canadian landscape and timelines for strategic decision-making

Let's connect and discuss how we can support your Canadian market access journey!

We're committed to your privacy. MORSE may use the information you provide to us to contact you about our relevant content and services. Your name, address and all other personal information will not be sold or given to any other organization or list distributor. You may unsubscribe from these communications at any time. For more information, check out our Privacy Policy.